BlackRock
ESPR

BlackRock’s Esperion Therapeutics ESPR Stock Holding History

BlackRock’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.9M Buy
22,128,021
+4,275,594
+24% +$12M ﹤0.01% 2454
2026
Q1 		$48.9M Buy
17,852,427
+170,226
+1% +$539K ﹤0.01% 2515
2025
Q4 		$65.4M Buy
17,682,201
+2,848,410
+19% +$9.2M ﹤0.01% 2358
2025
Q3 		$39.3M Buy
14,833,791
+120,726
+0.8% +$233K ﹤0.01% 2655
2025
Q2 		$14.5M Buy
14,713,065
+220,045
+2% +$220K ﹤0.01% 3212
2025
Q1 		$20.9M Buy
14,493,020
+257,597
+2% +$475K ﹤0.01% 2913
2024
Q4 		$31.3M Sell
14,235,423
-29,552
-0.2% -$68.9K ﹤0.01% 2757
2024
Q3 		$23.5M Buy
14,264,975
+281,313
+2% +$568K ﹤0.01% 2925
2024
Q2 		$31M Buy
13,983,662
+11,144,842
+393% +$26.2M ﹤0.01% 2716
2024
Q1 		$7.61M Buy
2,838,820
+725,921
+34% +$1.76M ﹤0.01% 3490
2023
Q4 		$6.32M Buy
2,112,899
+145,020
+7% +$188K ﹤0.01% 3596
2023
Q3 		$1.93M Buy
1,967,879
+660,427
+51% +$956K ﹤0.01% 4010
2023
Q2 		$1.82M Sell
1,307,452
-3,515,736
-73% -$4.91M ﹤0.01% 4089
2023
Q1 		$7.67M Sell
4,823,188
-685,999
-12% -$3.54M ﹤0.01% 3457
2022
Q4 		$34.3M Buy
5,509,187
+950,543
+21% +$6.8M ﹤0.01% 2713
2022
Q3 		$30.5M Buy
4,558,644
+264,412
+6% +$1.82M ﹤0.01% 2784
2022
Q2 		$27.3M Buy
4,294,232
+530,492
+14% +$3.01M ﹤0.01% 2909
2022
Q1 		$17.5M Buy
3,763,740
+1,522,523
+68% +$6.53M ﹤0.01% 3253
2021
Q4 		$11.2M Buy
2,241,217
+235,083
+12% +$1.88M ﹤0.01% 3604
2021
Q3 		$24.2M Sell
2,006,134
-79,213
-4% -$1.15M ﹤0.01% 3159
2021
Q2 		$44.1M Sell
2,085,347
-61,049
-3% -$1.47M ﹤0.01% 2785
2021
Q1 		$60.2M Buy
2,146,396
+82,191
+4% +$2.42M ﹤0.01% 2505
2020
Q4 		$53.7M Buy
2,064,205
+38,501
+2% +$1.15M ﹤0.01% 2423
2020
Q3 		$75.3M Sell
2,025,704
-63,192
-3% -$2.5M ﹤0.01% 2062
2020
Q2 		$107M Buy
2,088,896
+134,909
+7% +$5.64M ﹤0.01% 1799
2020
Q1 		$61.6M Sell
1,953,987
-114,245
-6% -$6.03M ﹤0.01% 1936
2019
Q4 		$123M Sell
2,068,232
-46,931
-2% -$2.11M ﹤0.01% 1838
2019
Q3 		$77.5M Buy
2,115,163
+131,743
+7% +$5.22M ﹤0.01% 2034
2019
Q2 		$92.3M Buy
1,983,420
+125,747
+7% +$5.91M ﹤0.01% 1964
2019
Q1 		$74.6M Sell
1,857,673
-21,226
-1% -$952K ﹤0.01% 2057
2018
Q4 		$86.4M Sell
1,878,899
-6
-0% -$289 ﹤0.01% 1904
2018
Q3 		$83.4M Buy
1,878,905
+73,673
+4% +$3.38M ﹤0.01% 2082
2018
Q2 		$70.7M Buy
1,805,232
+316,635
+21% +$16M ﹤0.01% 2157
2018
Q1 		$108M Sell
1,488,597
-16,798
-1% -$1.23M 0.01% 1795
2017
Q4 		$99.1M Sell
1,505,395
-16,279
-1% -$876K ﹤0.01% 1887
2017
Q3 		$76.3M Buy
1,521,674
+243,468
+19% +$11.7M ﹤0.01% 2017
2017
Q2 		$59.2M Sell
1,278,206
-3,738
-0.3% -$137K ﹤0.01% 2137
2017
Q1 		$45.3M Buy
1,281,944
+1,278,683
+39,211% +$29.3M ﹤0.01% 2285
2016
Q4 		$41K Sell
3,261
-140
-4% -$1.67K ﹤0.01% 3023
2016
Q3 		$47K Hold
3,401
– – ﹤0.01% 2984
2016
Q2 		$34K Buy
3,401
+2,518
+285% +$41.7K ﹤0.01% 3095
2016
Q1 		$15K Buy
883
+506
+134% +$8.14K ﹤0.01% 2982
2015
Q4 		$8K Hold
377
– – ﹤0.01% 2976
2015
Q3 		$9K Hold
377
– – ﹤0.01% 2769
2015
Q2 		$31K Sell
377
-4,399
-92% -$431K ﹤0.01% 2185
2015
Q1 		$443K Buy
+4,776
New +$308K ﹤0.01% 1559

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock's ESPR Position: Q2 2026 in Review

BlackRock increased its Esperion Therapeutics (ESPR) stake by 24% in Q2 2026, buying an estimated $12M and bringing the position to 22,128,021 shares worth $69.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2454.

BlackRock first reported a position in ESPR in Q1 2015 and has held it in 46 quarters since. The position peaked at $123M in Q4 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • BlackRock held 22,128,021 shares of Esperion Therapeutics worth $69.9M as of Q2 2026.
  • BlackRock bought 4,275,594 Esperion Therapeutics shares in Q2 2026, an estimated $12M.
  • Esperion Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2454 holding.
  • BlackRock first reported a position in Esperion Therapeutics in Q1 2015 and has held it in 46 quarters since.
  • BlackRock's Esperion Therapeutics position peaked at $123M in Q4 2019.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.